CDDO-Im

• Description :

  CDDO-Im (RTA-403) is an activator of Nrf2 and PPAR, with Kis of 232 and 344 nM for PPARα and PPARγ[1][2].

• Product Name Alternative :

  RTA-403; TP-235; CDDO-Imidazolide

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Ferroptosis; Keap1-Nrf2; PPAR

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; NF-κB; Vitamin D Related/Nuclear Receptor

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/CDDO-Im.html

• Purity :

  99.30

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  CC(C)([C@]1([H])CC[C@@]([C@@]2(CC[C@]3(CCC(C)(C[C@@]3([H])[C@]24[H])C)C(N5C=CN=C5)=O)C)6C)C(C(C#N)=C[C@]1(C)C6=CC4=O)=O

• Molecular Formula :

  C34H43N3O3

• Molecular Weight :

  541.72

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Place AE, et al. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res. 2003 Jul;9 (7) :2798-806.|[2]Liby K, et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res. 2005 Jun 1;65 (11) :4789-98.|[3]So JY, et al. A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer. PLoS One. 2014 Sep 17;9 (9) :e107616.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  PPARα; PPARγ

• CAS Number :

  [443104-02-7]